Neoadjuvant Camrelizumab/Chemo Combo Shows Clinical Activity in Locally Advanced ESCC

Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma.

Related Keywords

Peking ,Beijing ,China ,Chinese , ,Department Of Thoracic Surgery ,Union Medical College ,Chinese Academy Of Medical Sciences ,National Cancer Center Hospital ,Thoracic Surgery ,National Cancer ,Cancer Hospital ,Chinese Academy ,Medical Sciences ,Peking Union Medical College ,Camrelizumab ,Immunotherapy ,Neoadjuvant Camrelizumab ,Camrelizumab Plus Chemotherapy ,Locally Advanced Escc ,Escc ,Esophageal Squamous Cell Carcinoma ,La Escc ,Phase 3 Escort Neo Ncces01 Trial ,Asco Gi ,2024 Gastrointestinal Cancers Symposium ,Yin Li ,D ,